We provide you with 20 years of free, institutional-grade data for MDGL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MDGL. Explore the full financial landscape of MDGL stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-05 | 1157601 | MDGL | 10-Q | Url |
| 2025-05-01 | 1157601 | MDGL | 10-Q | Url |
| 2025-02-26 | 1157601 | MDGL | 10-K | Url |
| 2024-10-31 | 1157601 | MDGL | 10-Q | Url |
| 2024-08-07 | 1157601 | MDGL | 10-Q | Url |
| 2024-05-07 | 1157601 | MDGL | 10-Q | Url |
| 2024-02-28 | 1157601 | MDGL | 10-K | Url |
| 2023-11-06 | 1157601 | MDGL | 10-Q | Url |
| 2023-08-08 | 1157601 | MDGL | 10-Q | Url |
| 2023-05-09 | 1157601 | MDGL | 10-Q | Url |
| 2023-02-23 | 1157601 | MDGL | 10-K | Url |
| 2022-11-03 | 1157601 | MDGL | 10-Q | Url |
| 2022-08-04 | 1157601 | MDGL | 10-Q | Url |
| 2022-05-09 | 1157601 | MDGL | 10-Q | Url |
| 2022-02-24 | 1157601 | MDGL | 10-K | Url |
| 2021-11-04 | 1157601 | MDGL | 10-Q | Url |
| 2021-08-05 | 1157601 | MDGL | 10-Q | Url |
| 2021-05-06 | 1157601 | MDGL | 10-Q | Url |
| 2021-02-25 | 1157601 | MDGL | 10-K | Url |
| 2020-11-05 | 1157601 | MDGL | 10-Q | Url |
| 2020-08-06 | 1157601 | MDGL | 10-Q | Url |
| 2020-05-07 | 1157601 | MDGL | 10-Q | Url |
| 2020-02-26 | 1157601 | MDGL | 10-K | Url |
| 2019-11-06 | 1157601 | MDGL | 10-Q | Url |
| 2019-08-07 | 1157601 | MDGL | 10-Q | Url |
| 2019-05-08 | 1157601 | MDGL | 10-Q | Url |
| 2019-02-27 | 1157601 | MDGL | 10-K | Url |
| 2018-11-06 | 1157601 | MDGL | 10-Q | Url |
| 2018-08-07 | 1157601 | MDGL | 10-Q | Url |
| 2018-05-08 | 1157601 | MDGL | 10-Q | Url |
| 2018-03-13 | 1157601 | MDGL | 10-K | Url |
| 2017-11-09 | 1157601 | MDGL | 10-Q | Url |
| 2017-08-10 | 1157601 | MDGL | 10-Q | Url |
| 2017-05-11 | 1157601 | MDGL | 10-Q | Url |
| 2017-03-31 | 1157601 | MDGL | 10-K | Url |
| 2016-11-14 | 1157601 | MDGL | 10-Q | Url |
| 2016-07-20 | 1157601 | MDGL | 10-Q | Url |
| 2016-05-10 | 1157601 | MDGL | 10-Q | Url |
| 2016-03-15 | 1157601 | MDGL | 10-K | Url |
| 2015-11-05 | 1157601 | MDGL | 10-Q | Url |
| 2015-08-06 | 1157601 | MDGL | 10-Q | Url |
| 2015-05-07 | 1157601 | MDGL | 10-Q | Url |
| 2015-03-12 | 1157601 | MDGL | 10-K | Url |
| 2014-11-06 | 1157601 | MDGL | 10-Q | Url |
| 2014-08-06 | 1157601 | MDGL | 10-Q | Url |
| 2014-05-08 | 1157601 | MDGL | 10-Q | Url |
| 2014-03-11 | 1157601 | MDGL | 10-K | Url |
| 2013-11-04 | 1157601 | MDGL | 10-Q | Url |
| 2013-08-01 | 1157601 | MDGL | 10-Q | Url |
| 2013-04-30 | 1157601 | MDGL | 10-Q | Url |
| 2013-03-14 | 1157601 | MDGL | 10-K | Url |
| 2012-11-06 | 1157601 | MDGL | 10-Q | Url |
| 2012-08-02 | 1157601 | MDGL | 10-Q | Url |
| 2012-05-03 | 1157601 | MDGL | 10-Q | Url |
| 2012-02-22 | 1157601 | MDGL | 10-K | Url |
| 2011-11-03 | 1157601 | MDGL | 10-Q | Url |
| 2011-08-04 | 1157601 | MDGL | 10-Q | Url |
| 2011-05-05 | 1157601 | MDGL | 10-Q | Url |
| 2011-03-11 | 1157601 | MDGL | 10-K | Url |
| 2010-11-04 | 1157601 | MDGL | 10-Q | Url |
| 2010-08-09 | 1157601 | MDGL | 10-Q | Url |
| 2010-05-04 | 1157601 | MDGL | 10-Q | Url |
| 2010-03-11 | 1157601 | MDGL | 10-K | Url |
| 2009-11-04 | 1157601 | MDGL | 10-Q | Url |
| 2009-08-04 | 1157601 | MDGL | 10-Q | Url |
| 2009-05-07 | 1157601 | MDGL | 10-Q | Url |
| 2009-03-26 | 1157601 | MDGL | 10-K | Url |
| 2008-11-13 | 1157601 | MDGL | 10-Q | Url |
| 2008-08-07 | 1157601 | MDGL | 10-Q | Url |
| 2008-05-14 | 1157601 | MDGL | 10-Q | Url |
| 2008-03-20 | 1157601 | MDGL | 10-K | Url |
| 2007-11-13 | 1157601 | MDGL | 10-Q | Url |
| 2007-08-06 | 1157601 | MDGL | 10-Q | Url |
| 2007-05-07 | 1157601 | MDGL | 10-Q | Url |
| 2007-03-28 | 1157601 | MDGL | 10-K | Url |
| 2006-11-22 | 1157601 | MDGL | S-1 | Url |
| 2005-01-18 | 1157601 | MDGL | S-1 | Url |
Madrigal Pharmaceuticals, Inc(NASDAQ:MDGL) 
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormon...
Website: http://www.madrigalpharma.com
Founded: 2011
Full Time Employees: 29
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about MDGL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.